Download
s00059-020-04998-w.pdf 574,94KB
WeightNameValue
1000 Titel
  • Medikamentöse Sekundärprävention bei Patienten mit peripherer arterieller Verschlusskrankheit
1000 Titelzusatz
  • Medication-based secondary prevention in patients with peripheral arterial occlusive disease
1000 Autor/in
  1. Gebauer, Katrin |
  2. Wintersohl, Kerstin |
  3. Kraska, Rike |
  4. Kortendick, Katja |
  5. Fahrland, Ulrike |
  6. Freisinger, Eva |
  7. Meyborg, Matthias |
  8. Stella, Jacqueline |
  9. Engelbertz, Christiane |
  10. Reinecke, Holger |
  11. Malyar, Nasser |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-11-18
1000 Erschienen in
1000 Quellenangabe
  • 46(Suppl 2):280-286
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00059-020-04998-w |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413156/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Peripheral arterial occlusive disease (PAOD) is an atherosclerotic vascular disease with high morbidity and mortality. A consistent medication-based secondary prevention is part of the essential and evidence-based treatment of PAOD. The aim of this study was to ascertain the status quo of medicinal secondary prevention based on submitted prescriptions.!##!Methods!#!In the time period from 2014 to 2017 patients with a confirmed PAOD coding (I70.2-/I73.9-) were identified based on secondary data of the Association of Statutory Health Insurance Physicians Westphalia-Lippe (KVWL). The prescriptions submitted with respect to platelet inhibitors, oral anticoagulants, lipid lowering therapy (LLT) and angiotensin-converting enzyme (ACE) inhibitors in the fourth quarter year after diagnosis coding were collated.!##!Results!#!In the diagnosis period 2014/2015 a total of 238,397 patients had PAOD in the catchment area of the KVWL. The proportion of submitted prescriptions in the fourth quarter year after diagnosis was 25.9% for LLT, 13.6% for acetylsalicylic acid, 4.5% for clopidogrel, 5.5% for vitamin K antagonists (VKA), 3.5% for non-vitamin K‑dependent oral anticoagulants (NOAC) and 26.8% for ACE inhibitors. Over the course of the 3 years (n = 241,375 patients with PAOD 2016/2017) the proportion of submitted prescriptions for all substances except VKA increased (p < 0.001), whereby the largest relative increase was noted for NOAC (relative increase of 81.7%).!##!Conclusion!#!The guideline-conform medicinal secondary prevention in patients with PAOD in Germany is still in need of improvement. A consistent implementation of evidence-based medicinal secondary prevention harbors a great potential for improvement of the overall prognosis in patients with PAOD.
1000 Sacherschließung
lokal Atherosklerose
lokal Peripheral Arterial Disease/drug therapy [MeSH]
lokal Risikofaktoren
lokal Health services research
lokal Peripheral Arterial Disease/prevention
lokal Arterial Occlusive Diseases [MeSH]
lokal Humans [MeSH]
lokal Atherosclerosis
lokal Platelet Aggregation Inhibitors/therapeutic use [MeSH]
lokal Prognosis
lokal Risk factors
lokal Originalien
lokal Drug prescriptions
lokal Aspirin [MeSH]
lokal Peripheral Arterial Disease/epidemiology [MeSH]
lokal Anticoagulants/therapeutic use [MeSH]
lokal Secondary Prevention [MeSH]
lokal Prognose
lokal Versorgungsforschung
lokal Arzneiverordnungen
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/R2ViYXVlciwgS2F0cmlu|https://frl.publisso.de/adhoc/uri/V2ludGVyc29obCwgS2Vyc3Rpbg==|https://frl.publisso.de/adhoc/uri/S3Jhc2thLCBSaWtl|https://frl.publisso.de/adhoc/uri/S29ydGVuZGljaywgS2F0amE=|https://frl.publisso.de/adhoc/uri/RmFocmxhbmQsIFVscmlrZQ==|https://frl.publisso.de/adhoc/uri/RnJlaXNpbmdlciwgRXZh|https://frl.publisso.de/adhoc/uri/TWV5Ym9yZywgTWF0dGhpYXM=|https://frl.publisso.de/adhoc/uri/U3RlbGxhLCBKYWNxdWVsaW5l|https://frl.publisso.de/adhoc/uri/RW5nZWxiZXJ0eiwgQ2hyaXN0aWFuZQ==|https://frl.publisso.de/adhoc/uri/UmVpbmVja2UsIEhvbGdlcg==|https://frl.publisso.de/adhoc/uri/TWFseWFyLCBOYXNzZXI=
1000 Hinweis
  • DeepGreen-ID: 54ebbacf763046e9a7c9d27b3fe2657f ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6441973.rdf
1000 Erstellt am 2023-04-26T11:59:32.071+0200
1000 Erstellt von 322
1000 beschreibt frl:6441973
1000 Zuletzt bearbeitet 2023-10-19T11:31:16.826+0200
1000 Objekt bearb. Thu Oct 19 11:31:16 CEST 2023
1000 Vgl. frl:6441973
1000 Oai Id
  1. oai:frl.publisso.de:frl:6441973 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source